Skip to main content

Peer Review reports

From: Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

Original Submission
2 Feb 2022 Submitted Original manuscript
18 Feb 2022 Author responded Author comments - Eréndira Mejía-Aranguré
Resubmission - Version 2
18 Feb 2022 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
27 Apr 2022 Reviewed Reviewer Report
4 May 2022 Reviewed Reviewer Report
13 Jun 2022 Author responded Author comments - Eréndira Mejía-Aranguré
Resubmission - Version 4
13 Jun 2022 Submitted Manuscript version 4
27 Jun 2022 Reviewed Reviewer Report
1 Jul 2022 Reviewed Reviewer Report
18 Aug 2022 Author responded Author comments - Eréndira Mejía-Aranguré
Resubmission - Version 5
18 Aug 2022 Submitted Manuscript version 5
2 Sep 2022 Reviewed Reviewer Report
1 Oct 2022 Author responded Author comments - Eréndira Mejía-Aranguré
Resubmission - Version 6
1 Oct 2022 Submitted Manuscript version 6
5 Oct 2022 Author responded Author comments - Eréndira Mejía-Aranguré
Resubmission - Version 7
5 Oct 2022 Submitted Manuscript version 7
Publishing
10 Oct 2022 Editorially accepted
14 Dec 2022 Article published 10.1186/s12913-022-08676-x

You can find further information about peer review here.

Back to article page